HOME
HIV and AIDS
Hepatitis B
Hepatitis C
HIV-HCV Coinfection
HIV-HBV Coinfection
HIV and AIDS Articles on:
  FDA-approved Treatments
 
Experimental Treatments
 
Top New Articles
HOME PAGE

Laboratory Tests for Monitoring HIV-1 Infection
By Daniel R. Kuritzkes, MD
Director of AIDS Research, Brigham and Women's Hospital Associate Professor of Medicine, Harvard Medical School

FDA- Approved Tests for HIV

I.        Drug Resistance Testing in HIV-1 Infection    Top
           Clinical Significance of Drug Resistance in HIV-1 Infection
       
    Genotype and Phenotype
          How Resistance Tests are Done
           Genotypic Assays
           Phenotypic Assays
           Genotyping vs Phenotyping: Advantages and Disadvantages
           Interpreting Resistance Tests
              The Virtual Phenotype
           Prognostic Value of Resistance Testing

          Prospective Trials of Drug Resistance Testing
           Viradapt
           GART
           HAVANA
           VIRA3001
           NARVAL
           The Inhibitory Quotient (IQ)
           When and How to Use Resistance Testing


II.       Diagnosing HIV Infection     Top
           HIV ELISAs and Western Blots
            Rapid HIV Tests
            Home Testing for HIV Infection
            Virus Culture
          
 p24 Antigen Assays
          PCR Assays
             Qualitative Assays for Proviral HIV-1 DNA


III.      Virus Load Testing     Top
           Clinical Utility of Plasma HIV-1 RNA Monitoring
            Sample Collection


IV.      Immunologocal Testing     Top
            CD4 Counts
            Other Flow Cytometry Markers
            Functional Assays
            Proliferation Assays
            Cytotoxic T Lymphocyte Assays


V.      Therapeutic Drug Level Monitoring     Top


VI.     Glossary of Terms     Top


VII.    References     Top


VIII. Tables     Top
             Major Drug Resistance Mutations
             Web Sites for Interpreting Resistance Test Results
             Characteristics of Assays for Quantification of Plasma HIV-1 RNA
             Association of Plasma HIV-RNA Level with Declining CD4+Cell Count
              and Risk of AIDS and Death

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors (PIs)
Note: Most PIs are now used in combination with low-dose ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase  Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)